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Background: Waist circumference threshold values used in sub-Saharan Africa correspond to those of European
populations and are therefore inappropriate. Thus, they may over predict insulin resistance, especially in hypertensive
Africans, in whom there is often no association between blood pressure and insulin resistance. Using bioelectrical
impedance measurement in sub-Saharan Africa could possibly be advantageous to overcome the shortcomings of waist
circumference measurement. The aim of this study was to evaluate the contribution of body composition estimation by
bioelectrical impedance to predict cardiometabolic risk in Congolese hypertensive subjects.
Methods: Cardiovascular profiling and body composition analysis by bioelectrical impedance was measured in 400
patients (men = 40%; age = 51.1 ± 12.6 years). Patients were diagnosed with a metabolic syndrome (MS) according to the
IDF Criteria with and without the “blood pressure” criterion to remove any confounding autocorrelation bias, a visceral
fat-MS (with and without the “blood pressure” criterion) being defined by the presence of≥ 2 criteria with the precondition
of excess visceral fat defined by a bio impedance measurement score >10/30. Total cardiovascular risk was assessed using
the criteria of Framingham-2008.
Results: The frequencies of enlarged waist circumference (71.9% vs 68.9%, p = 0.52) and IDF-MS without blood pressure
criterion (24.9% vs 21.9%, p = 0.48) were similar among hypertensive vs. non hypertensive however excess visceral fat
(57.6% vs 33.8%, p <0.0001) as well as visceral fat-MS without blood pressure criterion (18.9% vs 11.3%, p = 0.04) were more
prevalent among hypertensive. Finally, total cardiovascular risk as well as arterial hypertension risk were associated with
visceral fat, but not with waist circumference (p > 0.05).
Conclusions: Pending the determination of thresholds values for pathological waist circumference adapted to sub-Saharan
populations, using bioelectrical impedance measurement may contribute to better characterize the cardiometabolic risk
and the insulin resistant phenotype of hypertensive sub-Saharan Africans.
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Arterial hypertension (AHT) is a global public health prob-
lem affecting more than one billion individuals [1]. This
worldwide increase in prevalence is conducted mainly by in-
creased life expectancy [2] and by the epidemic of obesity
and metabolic syndrome (MS) [3]. The mechanisms under-
lying the association between AHTand obesity are complex,
with a major contribution from insulin resistance and com-
pensatory hyperinsulinaemia [4]. The latter is associated
with whole-body and visceral fat (VF), chronic low-grade
systemic inflammation, abnormal glucose homeostasis, dys-
lipidemia, and elevated blood pressure [5], contributing to
the MS phenotype [6]. The MS increases cardiovascular
morbidity and mortality regardless of gender [7,8]. In hyper-
tensive subjects, the presence of a MS predicts higher total
cardiovascular (CV) risk and requires early and effective an-
tihypertensive therapy [9]. Screening for MS in hypertensive
patients may help identify a subset of patients requiring
stricter cardiovascular and cardio metabolic prevention.
The current 5-items screening criteria for the MS in-
clude enlarged waist circumference (WC) next to ele-
vated blood pressure (BP) and three biological
parameters (hyperglycemia, hypertriglyceridemia, and
hypo-HDL-cholesterolemia) [10], on which each one is
easily obtainable in order to facilitate diagnosis.
In sub-Saharan Africa, AHT is highly prevalent in its
population [11]. However, numerous studies reported a
lack of association between BP and insulin resistance in
the black population of this region [12].
On the other hand, there are currently few reliable re-
gional data from sub-Saharan Africa allowing to establish
consensual thresholds values for enlarged WC to be applied
to the general population [10] Thus, current guidelines rec-
ommend using threshold values as defined for European
populations to define enlarged WC in sub-Saharan Africans
[10], regardless of ethnic or regional disparities in bio an-
thropometrics and central fat distribution. However, some
studies show that the threshold values for pathological WC
need to be adjusted to African people, especially for the fe-
male gender [13-17]. Thus, relying on WC threshold values
currently recommended for sub-Saharan Africa remains in-
adequate and would certainly over predict insulin resistance,
especially in hypertensive subjects.
In addition, measurement of WC is operator-dependent
and prones to confounders, such as the respiratory cycle
and the postprandial state [18]. Moreover, this measure
does not discern subcutaneous from excess VF. [18].
Given these limitations, bioelectrical impedance is a sim-
ple, non-invasive and inexpensive means to qualitatively
estimate VF [19], previously validated against an unbiased
method to estimate body composition.
Using bioelectrical impedance in sub-Saharan African
hypertensive patients could possibly be advantageous to
overcome the shortcomings of WC measurement. Thepresent work has assessed whether body composition ana-
lysis by bioelectrical impedance outperforms WC meas-
urement to predict cardiometabolic risk in hypertensive




This cross-sectional study included patients of Black ances-
try, aged ≥20 years old and living in the province of South
Kivu (Democratic Republic of Congo), who attended the
clinic of general cardiology of the Provincial General Hos-
pital of Bukavu. The inclusion period ran from June 1st,
2010 to June 1st, 2012. Pregnant women, subjects with
edema, and bedridden patients were excluded from this
study.
The study was approved by the Ethics Committee of
the School of Medicine at catholic university of Bukavu.
Written informed consent for participation in the study
was obtained from participants.
Clinical measurements
For each patient, the medical history of AHT, diabetes
mellitus (DM) and tobacco smoking were investigated.
Then, each subject was placed still standing, size and
stature being measured with a meter stick, and WC with
a flexible tape at the end of mild expiration, between the
lower rib margins and the iliac crest. Thereafter, weight,
visceral fat, total body fat, skeletal muscle mass and body
mass index were measured using the OMRON BF510®
body composition monitor, which is fitted with eight ap-
plied sensors in hands and feet for accurate measure-
ment of whole-body electrical impedance. In 66 normal
subjects without a MS and with a Body Mass Index
(BMI) <27.5 kg.m-2 (without significant obesity or over-
weight), average visceral fat ±2SD amounted to 10.6/30,
with 95th percentile at 9.0/30, justifying the choice of
>10/30 to define excess visceral fat in the present study.
The same threshold value was also recommended by the
manufacturer.
Then, BP was measured using an electronic device
(Spengler TB-101) in a sitting position after the partici-
pants had remained seated for 5 minutes. The measure-
ments were taken twice, 2 min apart. The average of the
two consecutive measurements was retained for analysis.
At the end of the consultation, the patient was sent to the
laboratory for venous blood puncture on the forearm in
order to measure fasting glycaemia (with fasting period >
8 hours), cholesterol fractions and triglycerides.
A diagnosis of AHT was made when BP ≥ 140/90 mm Hg
and/or in the presence of a current hypotensive treatment
[9], diabetes mellitus (DM) was considered when fasting gly-
caemia was ≥ 126 mg/dl on two occasions [20] or when a
previous history of DM was present, and obesity was defined
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MS was defined according to the criteria proposed by the
International Diabetes Federation (IDF), which include, as
prerequisite, a WC ≥80 cm and ≥94 cm for women and
men, respectively [21], in association with two or more of
the following 4 criteria: fasting glycaemia ≥100 mg/dl or
DM; BP ≥130/85 mmHg or AHT; HDL-cholesterol levels
<50 mg/dl and <40 mg/dl, respectively, in women and
men; and fasting triglycerides ≥ 150 mg/dl in both genders.
Patients were also analyzed according to the presence of
an IDF-MS without the BP criterion (including patients
with scores ≥ 3/4) to remove any confounding autocorrel-
ation bias. In this study, a VF-MS phenotype (with and
without blood pressure criterion) was considered in theTable 1 General characteristics of the study population
All patients Men
n = 400 (100) n = 160 (40.0)
Men n (%) 160 (40.0) -
Age (years) 51.1 (12.6) 53.4 (13.5)
SBP (mmHg) 146.0 (24.8) 148.5 (23.5)
DBP (mmHg) 87.3 (15.2) 90.1 (15.3)
BMI (Kg/m2) 27.9 (5.3) 25.8 (3.9)
WC (cm) 95.0 (13.1) 93.7 (12.1)
MM (%) 27.7 (5.8) 32.9 (4.7)
VF (0/30-30/30) 9.8 (4.0) 10.8 (4.7)
BF (%) 36.1 (11.6) 25.9 (7.5)
Glycemia (mg/dl) 109.5 (48.4) 107.0 (41.7)
TC (mg/dl) 207.2 (56.9) 205.5 (50.3)
HDL-C (mg/dl) 46.3 (16.1) 44.4 (12.2)
LDL-C (mg/dl) 136.4 (49.2) 137.1 (47.0)
TG (mg/dl) 121.5 (69.9) 122.6 (83.7)
DM (%) 37.2 33.6
Obesity (%) 33.4 33.5
AHT (%) 62.3 61.9
WC≥ 80 cm (W) / 94 cm (M) 70.8 47.2
Glycemia > 100 mg/dl or DM 42.2 40.3
HDL-C < 50 mg/dl (W) / < 40 mg/dl (M) 45.9 39.6
TG > 150 mg/dl 25.8 22.1
BP ≥ 130/85 mmHg or AHT 81.3 83.9
VF ≥ 10/30 48.6 60.6
IDF-MS 47.4 30.4
IDF-MS without BP criteria 23.8 -
VF-MS 34.4 39.4
VF-MS without BP criteria 16.0 -
Framingham score (%) 13.4 (9.6) 17.4 (10.0)
AHT = arterial hypertension; BMI = body mass index; BP = blood pressure; SBP = syst
VF = visceral fat; BF = body fat; MM = skeletal muscle mass; TC = total cholesterol ; H
DM: diabetes mellitus.presence of at least two MS criteria excepted WC com-
bined with excess VF, defined as a bio impedance score ≥
10/30. Total cardiovascular (CV) risk was also assessed
using the criteria of Framingham-2008 [22].
Statistical analyses
Data from participants were processed using the Epi
INFO® 2000 version 3.5.3 and the 12.4.0 MedCalc® soft-
wares. Data are described, as frequencies or means ± 1
standard deviation or median (95% CI), when appropri-
ate. The distribution of the variables was tested for nor-
mality using the Kolmogorov-Smirnov test. We used 2
ways and 1 way analysis of variance (ANOVA) and





n = 240 (60.0) n = 249 (62.2) n = 151 (37.8)
- 99 (39.8) 61 (40.3) 0.87
49.6 (11.8) 0.003 55.0 (11.1) 44.6 (12.4) <0.0001
144.3 (25.5) 0.09 154.6 (21.4) 119.0 (11.8) <0.0001
85.6 (14.9) 0.004 91.5 (14.7) 74.4 (7.9) <0.0001
29.2 (5.7) <0.0001 28.1 (5.0) 27.4 (5.6) 0.26
95.9 (13.7) 0.09 95.7 (13.0) 94.0 (13.1) 0.08
24.3 (3.5) <0.0001 27.5 (5.3) 28.2 (6.5) 0.23
9.1 (3.3) <0.0001 10.5 (4.1) 8.6 (3.4) <0.0001
42.9 (8.5) <0.0001 36.4 (11.2) 35.5 (12.3) 0.48
111.4 (53.0) 0.43 106.6 (47.1) 114.4 (50.3) 0.16
208.2 (60.8) 0.64 210.4 (56.9) 201.9 (56.6) 0.06
47.6 (18.1) 0.055 46.6 (15.6) 46.0 (16.8) 0.21
136.1 (50.5) 0.85 138.6 (50.5) 132.8 (46.8) 0.26
120.8 (59.5) 0.81 125.9 (75.9) 114.4 (58.4) 0.11
39.9 0.24 37.7 36.4 0.80
43.8 <0.0001 34.4 31.8 0.59
62.5 0.89 100 0.0 -
86.3 <0.0001 71.9 68.9 0.52
43.5 0.51 43.1 40.7 0.62
50.0 0.04 45.0 47.3 0.66
28.2 0.18 26.7 24.2 0.57
78.8 0.21 100.0 50.3 <0.0001
41.5 0.0002 57.6 33.8 <0.0001
58.3 <0.0001 53.3 38.3 0.003
- - 24.9 21.9 0.48
31.1 0.08 44.7 18.0 <0.0001
- - 18.9 11.3 0.04
10.8 (8.3) <0.0001 16.4 (9.3) 8.7 (7.9) <0.0001
olic blood pressure; DBP = diastolic blood pressure; WC = waist circumference;
DL = high density lipoprotein; LDL = low density lipoprotein; TG = triglycerides;
Table 2 Total cardiovascular risk on the patients studied
Framingham score (%)
All patients Men Women
13.4 (9.6) 17.4 (10.0) 10.8 (8.3)
BMI Quartile (Kg/m2) [median (95% CI)]
1st quartile [22.0 (22.0 to 23.0)] 13.1 (10.2) 15.6 (11.0) 10.2 (8.4)
2nd quartile [26.0 (26.0 to 26.0)] 15.2 (10.0) 18.7 (9.9) 10.8 (8.4)
3rd quartile [29.0 (29.0 to 30.0)] 13.2 (8.9) 18.2 (8.6) 10.7 (8.1)
4th quartile [34.0 (33.0 to 35.9)] 12.1 (9.0) 17.9 (9.8) 11.1 (8.5)
p 0.17 0.40 0.95
WC Quartile (cm) [median (95% CI)]
1st quartile [79.0 (77.7 to 81.0)] 11.6 (10.0) 14.7 (11.1) 9.3 (8.5)
2nd quartile [91.0 (90.0 to 92.0)] 13.8 (9.2) 18.9 (9.4) 10.2 (7.1)
3rd quartile [99.0 (98.6 to 100)] 14.1 (9.6) 18.2 (9.4) 11.1 (8.6)
4th quartile [108.5 (108.0 to 110)] 14.3 (9.5) 18.8 (9.5) 12.4 (8.9)
p 0.17 0.18 0.20
VF Quartile (/30) [median (95% CI)]
1st quartile [6.0 (5.0 to 6.0)] 10.8 (9.4) 14.7 (10.7) 8.6 (7.6)
2nd quartile [9.0 (8.0 to 9.0)] 10.1 (8.6) 15.0 (10.2) 8.7 (7.5)
3rd quartile [11.0 (10.0 to 11.0)] 14.7 (8.8) 17.7 (9.6) 13.1 (8.0)
4th quartile [15.0 (14.0 to 15.0)] 18.7 (9.3)* 19.7 (9.2)* 16.3 (9.1)*
p <0.0001 0.04 <0.0001
*p < 0.05 compared to the 1st, 2nd and the 3rd quartiles.
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the chi-square test for comparison of proportions. The as-
sociation between quantitative variables was modeled using
general linear regression stepwise method and that between
qualitative variables using logistic regression. A p value
<0.05 was considered for statistical significance.
Results
General Characteristics of the study population
The Table 1 presents the general characteristics of the
study population. In total, four hundred (400) patients
were included in the study. Average values were: 51.1 ±
12.6 years for age; 27.9 ± 5.3 kg/m2 for BMI; 95.0 ±
13.1 cm for WC; 9.8/30 ± 4.0/30 for VF.
Both frequency of obesity (43.8% vs. 33.5%; p < 0.0001)
and large WC (86.3% vs. 47.2%; p < 0.0001) were high in
women than in men respectively. However, men presented
significantly higher VF (10.8 ± 4.7/30 vs. 9.1 ± 3.3/30; p <
0.0001) and diastolic BP (90.1 ± 15.3 mmHg vs. 85.6 ±
14.9 mmHg; p = 0.004) than women.
Compared to normotensive patients (37.8%), hyperten-
sive patients (62.2%) had a significantly higher age (55.0 ±
11.1 years vs 44.6 ± 12.4 years; p <0.0001) and VF score
(10.5/30 ± 4.1/30 vs 8.6/30 ± 3.4/30; p <0.0001), whereas
values were not statistically different with respectively
BMI, WC, and other biological parameters (p > 0.05) be-
tween groups.
Total cardiovascular risk in the studied population
The Table 2 reports total CV risk of our sample. Total CV
risk of the studied population was 13,4 ± 9.6%. Total CV
risk was significantly higher in men than women (17.4 ±
10.0% vs 10.8 ± 8.3; p < 0.0001). Moreover, patients in the
4th VF quartile had a total CV risk significantly higher than
those in the 3rd lower quartiles in total as well in men and
women separately (p < 0.05).
However, the total CV risk was similar between quartiles
of BMI and WC in men and women (p > 0.05).
In stepwise general linear regression (Table 3), total
CV risk was associated to VF (β coefficient = 0.24; partial
r = 0.15; p = 0.002) and age. WC and BMI were rejected
by the model (p > 0.05).
Metabolic syndrome parameters
Table 1 reports the frequencies of the various compo-
nents of the MS. In total, the frequency was respectively
47.4% for IDF-MS and 34.4% for VF-MS (p = 0.0003).
Compared to men, the frequencies were higher in
women significantly for large WC (86.3% vs 47.2%; p <
0.0001) and IDF-MS (58.3% vs 30.4%; p < 0.0001). How-
ever, similar values of VF-MS were found in both sexes
(Men vs women: 39.4% vs 31.1%; p = 0.08).
Compared to non-hypertensive participant, hyperten-
sive ones had a frequency of IDF-MS significantly higher(53.0% vs 38.0%; p = 0.003). However, the frequency of
IDF-MS was similar in the 2 groups when the BP criter-
ion was excluded (24.9% vs 21.9%; p = 0.48). Moreover,
VF-MS with BP criterion (44.7% vs 18.0%; p < 0.0001) or
without BP criterion (18.9% vs 11.3%; p = 0.04) remained
significantly higher in the group of hypertensive patient
than in the group of non-hypertensive patient.
Determinants of blood pressure
The results of the general linear regression using step-
wise method of BP according to the alleged risk factors
are listed in Table 3. There was a significant positive as-
sociation between systolic BP and VF (β coefficient =
0.75 mmHg; p = 0.01), and between diastolic BP and VF
(β coefficient = 0.61 mmHg; p = 0.001) after adjusting
for confounders factors. WC was not included in the
model.
Determinants of arterial hypertension
Table 4 shows the odds ratio for AHT by DM and quar-
tiles of age, BMI, WC and VF, respectively. The results of
the multivariate logistic regression show that, compared to
patients in the 1st VF quartile, patients in the 4th visceral
fat quartile were 2.9 times more frequently hypertensive
after adjusting for age, BMI and WC (p <0.05). By con-
trast, the difference was not statistically significant for WC
(p > 0.05).
Table 3 Multivariate linear stepwise regression analysis of Waist circumference, visceral fat, systolic blood pressure,
diastolic blood pressure and total cardiovascular risk respectively according to the alleged risk factors
β coefficient Standard error Partial r p
WC (cm)
BMI (Kg/m2) 1.44 0.09 0.59 <0.0001
VF (0/30) 0.94 0.13 0.33 <0.0001
not included in the model (a)
VF (0/30)
Age (years) 0.07 0.009 0.36 <0.0001
Gender F(1) / M (2) 3.14 0.25 0.52 <0.0001
BMI (Kg/m2) 0.46 0.03 0.54 <0.0001
WC (cm) 0.05 0.01 0.20 <0.0001
SBP (mmHg)
Age (years) 0.66 0.09 0.32 <0.0001
VF (/30) 0.75 0.29 0.12 0.01
Not included in the model (b)
DBP (mmHg)
Gender F (1) / M (2) 3.62 1.54 0.11 0.01
VF (/30) 0.61 0.18 0.16 0.001
Not included in the model (c)
Total cardiovascular risk (Framingham score)
Age (years) 0.57 0.02 0.75 <0.0001
VF (/30) 0.24 0.07 0.15 0.002
Not included in the model (d)
(a) Age, gender; (b) BMI, gender, WC, total cholesterol; (c) Age, WC, BMI, total cholesterol (d) WC, BMI.
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AHT and VF became statistically meaningless (p = 0.055),
age was the major determinant.
Discussion
This analysis of four hundred indigenous patients from
South Kivu attending the outpatient cardiology clinic of
Bukavu Reference General Provincial Hospital shows
that bioelectrical impedance provides better discrimin-
ation between hypertensive and normotensive patients
as regards visceral fat accumulation compared to stand-
ard metabolic syndrome criteria, including waist circum-
ference, which were similar in both groups. In addition,
visceral fat accumulation, unlike waist circumference,
was significantly associated with total cardiovascular risk
and arterial hypertension risk.
These results demonstrate the usefulness of measuring
body composition by bioelectrical impedance to grade
visceral fat accumulation, a major driver of insulin resist-
ance, in hypertensive patients. Previously, Aydin M et al.
reported that visceral fat estimated by bioelectrical im-
pedance was significantly associated with low-grade sys-
temic inflammation in Turkish adults [23]. Bioelectrical
impedance is a validated unbiased method to estimatebody composition, and an OMRON monitor fitted with 8
sensors at hands and feet for accurate measurement of
whole-body electrical impedance, identical to that used for
this study, was previously shown to have excellent correl-
ation with both magnetic resonance imaging (MRI) and
dual X-ray absorptiometry (DEXA) for estimating fat mass
(r = 96%) and visceral fat (r = 92%), respectively [19]. Bio-
electrical impedance is also advantageous in being more
accessible in terms of cost and implementation than MRI,
more cumbersome in terms of hardware, cost and staff
training [24].
Two relevant observations derived from the present
study. The first is that body composition estimated by bio-
electrical impedance showed a high frequency of visceral
fat accumulation in hypertensive vs normotensive patients
in a South-Kivu population. Moreover, although Saad MF
et al. reported that the association between blood pressure
and insulin resistance was limited to Caucasians and ab-
sent among blacks and PIMA Indians [12], the present ob-
servation suggests a role for excess visceral fat (and insulin
resistance) in the pathogenesis of arterial hypertension in
black subjects corroborating other authors [25]. We noted,
however, that another study reported a lack of correlation
between blood pressure and insulin resistance in diabetic








1st quartile 1 1 1
2nd quartile 2.3 (1.2 to 4.2)* 1.2 (0.4 to 3.5) 3.7 (1.7 to 7.8)*
3rd quartile 4.3 (2.2 to 8.5)* 2.0 (0.7 to 5.7) 7.9 (3.1 to 19.6)*
4fh quartile 9.3 (4.4 to 19.6)* 4.3 (1.5 to 11.9)* 23.5 (7.1 to 77.9)*
BMI (Kg/m2)
1st quartile 1 1 -
2nd quartile 1.9 (0.8 to 4.2) 1.6 (0.3 to 8.3) -
3rd quartile 2.1 (0.8 to 5.3) 3.3 (0.3 to 31.8) -
4fh quartile 2.0 (0.7 to 5.7) 2.1 (0.1 to 25.1) -
WC (cm)
1st quartile 1 1 -
2nd quartile 1.0 (0.5 to 2.1) 2.1 (0.1 to 25.1) -
3rd quartile 0.4 (0.1 to 1.0) 0.3 (0.07 to 1.5) -
4fh quartile 0.5 (0.1 to 1.4) 0.2 (0.03 to 2.1) -
VF (/30)
1st quartile 1 1 1
2nd quartile 0.8 (0.4 to 1.7) 1.1 (0.3 to 4.1) 0.7 (0.3 to 1.5)
3rd quartile 1.4 (0.6 to 3.4) 1.8 (0.3 to 9.6) 1.2 (0.5 to 2.7)
4fh quartile 2.9 (1.0 to 7.8)* 7.3 (0.9 to 55.6) 0.9 (0.2 to 3.3)
DM -
*p<0.05.
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confounding effect of a high frequency of atypical diabetes
mellitus (ie. without insulin resistance) among these dia-
betic patients. High blood pressure in that study was asso-
ciated with other determinants, including age and chronic
kidney disease [26].
The second observation is the lack of difference in the fre-
quency of MS between hypertensive and normotensive pa-
tients when blood pressure criteria were removed from the
definition of the MS. By contrast, substituting the WC cri-
terion with that of “high visceral fat” measured by bioelec-
trical impedance in the definition of the MS (with or
regardless the blood pressure criterion) allowed for separat-
ing hypertensive from non-hypertensive patients. In
addition, visceral fat, but not WC, was associated with total
cardiovascular risk. Taken together, these results suggest a
clear relevance of measuring visceral fat (as proxy for insulin
resistance) to better characterize cardio metabolic risk in
these Congolese hypertensive patients. Indeed, several limi-
tations of the current criteria of the MS are particularly rele-
vant and applicable to South Kivutians. First, the “waist”
criterion extrapolated from Caucasian populations is not
suitable to sub-Saharan Africans. [10] In addition, innate
hypotriglyceridemia is frequent black populations, both in
indigenous groups and in longstanding expatriates (such asAfrican-Americans) or in contemporary migrants. [27] Simi-
larly, DM without insulin resistance is common in this
region [20]. Finally, some authors reported a lack of associ-
ation between blood pressure and insulin resistance in
people from black ancestry [12]. Thus, defining the presence
of a MS using conventional criteria would be partly done
another common mechanism as age which increases the fre-
quency of all parameters of the metabolic syndrome [28].
This is unlikely in the present study.
The present study shows that higher visceral fat deter-
mined by bioelectrical impedance is an easy means to
document higher cardiometabolic risk, including excess
risk in hypertensive vs. normotensive patients. The asso-
ciation between cardiometabolic risk and visceral fat in
the present study could not be ascribed to a confound-
ing effect of other standard drivers of insulin resistance,
such as age, gender, BMI and WC.
An obvious limitation of this work lies in its transversal
design, which precludes drawing causal inferences between
WC, visceral fat and cardiovascular events or cardiometa-
bolic morbidities’ incidence. Similarly, the reference method
of planimetry CT or DEXA to measure visceral fat could
not be used as a plain result of non-availability. Whereas the
bioimpedance method used in this study merely provides
with a semi-quantitative (0–30) scale to estimate visceral fat
Katchunga et al. BMC Cardiovascular Disorders  (2015) 15:17 Page 7 of 8accretion, is was nevertheless highly correlated with gold
standards methods, such as whole body magnetic reson-
ance imaging (MRI) and dual energy X-ray absorptiometry
(DEXA) in healthy normal-weight, overweight and obese
adults, [19]. In addition, the inclusion of subjects at high
cardiovascular risk may be biased by confounders of body
weight or body composition, including drug-induced body
weight or body composition changes as a result of di-
uretics and glucose-lowering therapies. Another potential
bias may arise from the fact that the cutoff value for
visceral fat used in this study was similar for men and
women, and do not equate real-life gender-adjusted
thresholds [29], and generalizing the present results to the
whole population needs confirmatory studies. For all these
limitations, it is likely that defining appropriate regional
threshold values for WC that would predict insulin resist-
ance will remain for long an ongoing debate. Our results
suggest that a simple estimation of visceral fat with a bio
impedance method may provide a useful alternative to
grade cardiometabolic risk in black populations.
Conclusions
This study shows that estimating body composition by
electrical bio impedance provides a simple, more precise
alternative to WC as surrogate to insulin resistance in
hypertensive Congolese. Thus, pending the determin-
ation of consensual population-based threshold values
for enlarged WC, the alternative use of bio-impedance
methods seems appropriate.
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